1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
PuraPharm Corp. Ltd.

PuraPharm Corp. Ltd.

HHKEX:1498
0.24
HKD
+0.00
(-1.24%)
189.94MMarket Cap
Mar 31Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
748.31
2.29
2.27
2.35
2.76
2.67
1.62
1.68
1.14
1.03
0.97
0.8
- -
Basic EPS, GAAP
70.39
0.14
0.14
0.01
0.08
-0.87
0.09
-0.31
-0.3
-0.27
-0.09
-0.08
- -
Free Cash Flow per Basic Share
40.34
-0.22
-0.49
-0.66
0.09
0.13
0.1
-0.05
0.16
0.15
0.22
0.06
- -
Dividend per Share
- -
- -
0.08
0.02
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.57
1.97
1.91
2.09
2.14
1.3
1.3
1.02
0.65
0.39
0.28
0.24
0.24
Tangible Book Value per Share
0.54
1.93
1.8
1.18
1.24
0.86
0.96
0.86
0.5
0.25
0.16
0.09
0.09
Basic Weighted Avg Shares
- -
207
237
252
270
261
371
394
395
395
395
419
430
Sales/Revenue/Turnover
366
474
536
592
746
696
602
660
448
407
382
336
- -
Operating Margin (%)
15.23
10.94
8.99
0.99
3.3
-6.29
11.92
6.52
-9.88
-9.12
-4.41
-6.66
- -
Depreciation Expense
14
13
17
27
37
67
48
50
49
49
55
45
- -
Net Income, GAAP
34
28
32
2
21
-227
32
-122
-120
-106
-35
-35
- -
Effective Tax Rate (%)
18.48
29.09
16.82
81.72
21.58
- -
21.15
- -
- -
- -
- -
- -
- -
Profit Margin (%)
9.41
6.01
6
0.32
2.79
-32.66
5.27
-18.48
-26.83
-26.07
-9.28
-10.48
- -
Working Capital
23
315
256
8
131
-41
16
-54
-179
-222
-223
-252
-252
LT Debt
- -
- -
- -
54
164
186
213
111
75
103
100
67
67
Total Equity
136
470
455
549
562
362
512
402
258
153
111
130
130
Return on Invested Capital (%)
- -
8.21
6.34
0.17
1.91
- -
5
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
7.82
6.09
0.55
3.44
- -
5.45
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
9.4
6.96
0.38
3.74
-49.17
7.26
-26.69
-36.44
-51.56
-26.8
-29.15
- -

Capital Structure

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
264
261
284
LT Borrowings
89
97
56
LT Finance Leases
10
16
12
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
395
395
535
Market Capitalization
217
194
190

Working Capital

HKD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
268
232
227
Cash, Cash Equivalents & STI
13
17
16
Accounts Receivable, Net
103
88
95
Inventories
124
83
99
Total Current Liabilities
491
448
479
Payables & Accruals
- -
- -
- -
ST Debt
264
261
284
Deferred Revenue
- -
- -
- -

Growth Rates

HKD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-8.23%
-21.59%
17.34%
Free Cash Flow
-46.44%
-119.07%
-70.67%
Net Income, GAAP
-95.06%
-112.93%
-0.61%
Sales/Revenue/Turnover
-2.05%
-9.96%
-12.03%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
407
2024
- -
- -
382
2025
- -
- -
336

Semi-annual Earnings Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.27
2024
- -
- -
-0.09
2025
- -
- -
-0.08

Semi-annual Dividends Per Share

HKD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yu Ling Chan
Full Time Employees
441
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Wireless Centre, Phase One Hong Kong Hong Kong
IPO Date
Jul 8, 2015
Website
purapharm.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
PuraPharm Corporation Limited (1498.HK), an investment holding company founded in 1998 and headquartered in Tai Po, Hong Kong, engages in the research, development, production, marketing, and sale of concentrated Chinese medicine granules (CCMG) under the Nong's brand and Chinese healthcare products; it operates through segments including China CCMG, Hong Kong CCMG, Chinese healthcare products, clinics, and plantation, with manufacturing facilities in Nanning, Guangxi, China, that comply with PRC GMP, Australian TGA, and CNAS ISO 17025 standards. The company offers over 600 CCMG products for professional use by Chinese medical practitioners, hospitals, and clinics, alongside over-the-counter health products under brands such as PuraGold, Oncozac, Haveron, and Immuzac; it provides Chinese medicine clinic management systems, operates Nong’s clinics offering diagnostic services and CCMG products, engages in raw Chinese herb plantation and trading, and sells traditional Chinese medicine decoction pieces through online platforms and healthcare institutions in Hong Kong, Mainland China, and internationally. PuraPharm holds the leading 70% market share in Hong Kong CCMG by prescription revenue and is the only non-PRC firm licensed by China NMPA to manufacture CCMG in China, with products recognized by the United States Pharmacopeia. Recent developments include the announcement in October 2025 of a discloseable and connected transaction involving a patent licence agreement with issuance of consideration shares under specific mandate and subscription of new shares; an interim report released in September 2025; appointment of a new independent non-executive director in August 2025; interim results for the six months ended 30 June 2025 announced in August; and a profit warning alongside the patent licence and share subscription proposals in July 2025, alongside ongoing capital reduction efforts and board changes earlier in 2025.